Top 10 Optometry Podcasts of 2025
The year in optometry: 10 stories that defined eye care in 2025
Qlosi™ Presbyopia Eye Drops: Candidacy, Dosing, and Real-World Wins
Orasis Expands Access to Qlosi With Starter Packs for ECPs
Can Eye Drops Replace Reading Glasses: Medical Miracle or Headline Hype?
Orasis expands access to presbyopia treatment with Qlosi starter packs
Orasis Launches Qlosi Starter Packs to Expand Access and Support Demand for Presbyopia Treatment
Presbyopia: Past, Present, and Pipeline
Qlosi demonstrates consistent pupil size reduction in presbyopia
Presbyopia Drops: A Foundation for Future Care
The mechanics of presbyopia: From muscle movement to functional vision
Modern intake strategies needed for changing presbyopia landscape
Presbyopia: The Future Is Here
Innovations in Presbyopia Management: The Role of Drop Therapy
The Next Chapter in Pharmacological Treatments for Presbyopia
Crazy New Info About Presbyopia Drops – Significant Findings
OI Show: We are getting close with Qlosi with Dr. Maria Pribis
Be Progressive
QLOSI™ EyeQ Formulation: Performance, Convenience, and Customization
Presbyopia Drops and Practice Growth: Learning from the Past, Looking to the Future
Prescription Eye Drops for Presbyopia
A Unique Formulation for Presbyopia Treatment
Patient Selection Criteria for Qlosi™ for Presbyopia
Near Vision Improvement Without Compromising Distance
A Safe and Effective Solution for Presbyopia
Qlosi in Focus – A Novel Formulation, Flexibility, and New Horizons in Presbyopia Treatment
Prescribing Qlosi™ for Presbyopic Retina Patients
Exploring Presbyopia Drops (QLOSI™) with Dr. Jade Coats
Seeing Fewer Patients and Earning More: Inside a Smarter Optometry Workflow with Dr. Janelle Davison
Helping a Patient’s Presbyopia Journey
A Changing Treatment Landscape for Presbyopia
The Evolution of Presbyopia Treatment
Medical Treatment for Presbyopia
Industry Insider
The Ultimate Guide to QLOSI™ for Presbyopia
Orasis Launches Presbyopia Eyedrop in US
OIS Pod Ep #415: Bringing Presbyopia Back to the Forefront
Orasis Launches Qlosi Corrective Eyedrop for Presbyopia
Qlosi Novel Corrective Eye Drop for Presbyopia Now Available to Prescribe in US
Orasis Launches Presbyopia Eyedrop Qlosi in the US
The science of formulation: Advancing presbyopia treatment through optimized design
SECO 2025 Preview: Orasis Shark Tank-Style Event and Qlosi Launch
Orasis gears up for US launch of Qlosi
Array of Options Available for Presbyopia Treatment
Age, Presbyopia Stage can Affect Treatment Journey
Top 5 startups in Ophthalmology in Israel in Feb, 2025
VIDEO: Qlosi Improves Functional Near Vision in Presbyopia
New Insight: A Look at Qlosi for Presbyopia with Elad Kedar, MBA
VIDEO: Orasis closes $78 million in financing
Pharmacologic Agents for Refractive Correction
VIDEO: CSF-1 Achieves, Maintains Functional Vision in Mild to Moderate Presbyopes
AAOpt 2024: Qlosi’s Effectiveness in Treatment of Presbyopia
CSF-1 Low-Dose Pilocarpine Improves Vision Outcomes in Presbyopia
Executive Updates: Orasis
VIDEO: Qlosi for presbyopia demonstrates near vision improvement, pupil size reduction
AAO 2024: Optimal Pupil Reduction Percentage for Near Vision Improvement in Presbyopia
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties
Orasis Completes Financing to Support Launch of Presbyopia Eye Drop Qlosi
Orasis Secures $78 Million to Support Commercial Launch of Qlosi
Orasis Secures Financing to Support US Commercial Launch of Qlosi
Orasis snags $78M to launch presbyopia eye drops more than a year after FDA approval
The FDA Approves Qlosi for the Treatment of Presbyopia
FDA Approves Qlosi for the Treatment of Presbyopia in Adults
Orasis Prepares to Battle AbbVie in Presbyopia
FDA Approves Qlosi for Treatment of Presbyopia in Adults
FDA approves Qlosi eye drop for treatment of presbyopia
Orasis gains FDA approval for presbyopia eye drops, following in AbbieVie’s footsteps
FDA Approves Second Presbyopia Drop
FDA Clears Orasis Pharmaceuticals’ Presbyopia Treatment
Eye Drops for Presbyopia Win FDA Approval
FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of presbyopia
FDA approves low-dose pilocarpine hydrochloride 0.4% as a treatment for presbyopia
FDA Approves Pilocarpine Hydrochloride Ophthalmic Solution to Treat Presbyopia
Orasis Receives FDA Approval for Presbyopia Eye Drop Qlosi
FDA Approves Orasis’s Qlosi for Presbyopia
